24/7 Market News Snapshot 11 August, 2025 – IO Biotech, Inc. Common Stock (NASDAQ:IOBT)

August 11, 2025

DENVER, Colo., 11 August, 2025 (www.247marketnews.com) – (NASDAQ:IOBT) are discussed in this article.
IO Biotech, Inc. (IOBT) has experienced a remarkable surge in trading, reaching $3.045, an astonishing 68.23% increase compared to its previous close of $1.810. This bullish momentum is reflected in a trading volume that exceeded 21.37 million shares, sparking significant interest among investors. The spike in stock price follows the announcement of compelling topline results from IO Biotech’s pivotal Phase 3 trial evaluating its innovative immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio®.

The Phase 3 study, which included 407 patients with unresectable or metastatic melanoma, assessed the efficacy of Cylembio in conjunction with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). Results indicated that patients receiving the combination treatment exhibited a substantial improvement in progression-free survival (PFS) compared to those who received pembrolizumab alone. Specifically, median PFS was reported at 19.4 months versus 11.0 months, reflecting a hazard ratio of 0.77. Notably, in the subset of patients naïve to prior anti-PD-1 treatment, the median PFS reached 24.8 months for those on combination therapy. Additionally, patients with PD-L1 negative tumors showed a pronounced benefit, achieving a median PFS of 16.6 months compared to just 3.0 months with pembrolizumab alone.

Dr. Mai-Britt Zocca, President and CEO of IO Biotech, expressed confidence in Cylembio’s therapeutic potential, particularly given the consistent improvements across various patient subgroups. The safety profile of the combination treatment was favorable, with no new safety signals reported. Following these promising trial results, IO Biotech intends to consult with regulatory authorities regarding potential approval pathways and will host a conference call to discuss further insights. This progress marks a pivotal moment for IO Biotech as it strives to enhance treatment options for patients with advanced melanoma.

Related news for (IOBT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.